Detection of Aberrant p16INK4A Methylation in Sera of Patients with Liver Cirrhosis and Hepatocellular Carcinoma

Journal of Korean Medical Science

Volumn 19, Issue 1, 2004, Pages 83-86

  Chu, Hyung Jun ^a   Heo, Jeong ^a   Seo, Soo Boon ^a   Kim, Gwang Ha ^a   Kang, Dae Hwan ^a   Song, Geun Am ^a   Cho, Mong ^a   Yang, Ung Suk ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

Carcinoma hepatocellular; Liver cirrhosis; p16INK4a methylation; PCR methylation specific

Indexed keywords

ALPHA FETOPROTEIN; PROTEIN P16; TUMOR MARKER; DNA; PROTEIN P16INK4A;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DNA METHYLATION; FEMALE; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SERUM; BLOOD; FIBROSIS; GENETICS; LIVER; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; SENSITIVITY AND SPECIFICITY; TIME; TUMOR SUPPRESSOR GENE;

AGED; CARCINOMA, HEPATOCELLULAR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA; DNA METHYLATION; FEMALE; FIBROSIS; GENES, P16; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 1542273254     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2004.19.1.83     Document Type: Article

References (26)

1. Korea National Statistical Office. Korea Statistical Yearbook. Daejeon 2002.
2. Shiina S, Tagawa K, Unuma T, Terano A Percutaneous ethanol injection therapy for treatment of hepatocellular carcinoma. Am J Reontgenol 1990; 154: 947-51.
3. Okuda S. Local ablation therapy for hepatocellular carcinoma. Semin Liver Dis 1999; 19: 323-8.
4. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31: 330-5.
5. Nagasue N, Uchida M, Makino Y, Takemoto Y, Yamanoi A, Hayashi T, Chang YC, Kohno H, Nakamura T, Yukaya H. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 1993; 105: 488-94.
6. Shimada M, Takenaka K, Gion T, Fujiwara Y, Kajiyama K, Maeda T, Shirabe K, Nishizaki T, Yanaga K, Sugimachi K. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996; 111: 720-6.
7. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutation in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
8. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis: A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000; 32: 970-9.
9. INK4 (MTS1) gene occur in a subset of patients with hepatocellular carcinoma. Hepatology 1997; 25: 1376-81.
10. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1: 686-92.
11. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-7.
12. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-46.
13. Tannapfel A, Wittekind C. Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis. Virchows Arch 2002; 440: 345-52.
14. Razin A. CpG methylation, chromatin structure and gene silencing: a three-way connection. EMBO J 1998; 17: 4905-7.
15. Kim JR, Kim SY, Kim MJ, Kim JH. Alterations of CDKN2 (MTS1/ p16INK4A) gene in paraffin-embedded tumor tissues of human stomach, lung, cervix and liver cancers. Exp Mol Med 1998; 30: 109-14.
16. Kita R, Nishida N, Fukuda Y, Azechi H, Matsuoka Y, Komeda T, Sando T, Nakao K, Ishizaki K. Infrequent alterations of the p16INK4A gene in liver cancers. Int J Cancer 1996; 67: 176-80.
17. Lin YW, Chen CH, Huang GT, Lee PH, Wang JT, Chen DS, Lu FJ, Sheu JC. Infrequent mutations and no methylation of CDKN2A (p16/MTS1) and CDKN2B(p15/MTS2) in hepatocellular carcinoma in Taiwan. Eur J Cancer 1998; 34: 1789-95.
18. Chaubert P, Gayer R, Zimmermann A, Fontolliet C, Stamm B, Bosman F, Shaw P. Germ-line mutations of the p16INK4 (MTS1) gene occur in a subset of patients with hepatocellular carcinoma. Hepatology 1997; 25: 1376-81.
19. Liew CT, Li HM, Lo KW, Leow CK, Chan JY, Hin LY, Lau WY, Lai PB, Lim BK, Huang J, Leung WT, Wu S, Lee JC. High frequency of p16INKA4 gene alterations in hepatocellular carcinoma. Oncogene 1999; 18: 789-95.
20. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, Lai PB, Lau WY, Hjelm NM, Johnson PJ. Detection of aberrant p16 methylation in the plasma and serum of liver cancers patients. Cancer Res 1999; 59: 71-3.
21. Roncalli M, Bianchi P, Bruni B, Laghi L, Destro A, Di Gioia S, Gennari L, Tommasini M, Malesci A, Coggi G. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology 2002; 36: 427-32.
22. Kaneto H, Sasaki S, Yamamoto H, Itoh F, Toyota M, Suzuki H, Ozeki I, Iwata N, Ohmura T, Satoh T, Karino Y, Satoh T, Toyota J, Satoh M, Endo T, Omata M, Imai K. Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut 2001; 48: 372-7.
23. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30.
24. Herman JG, Gaff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-6.
25. Wong IH, Lau WY, Leung T, Johnson PJ. Quantitative comparison of alpha-fetoprotein and albumin mRNA levels in hepatocellular carcinoma/adenoma, non-tumor liver and blood: implications in cancer detection and monitoring. Cancer Lett 2000; 156: 141-9.
26. Wong IH, Lo YM, Lai PB, Johnson PJ. Relationship of p16 methylation status and serum alpha-fetoprotein concentration in hepatocellular carcinoma patients. Clin Chem 2000; 46: 1420-2.